

# Lead Compound Identification of CD171 ADC for Solid Tumor Treatment

APITBIO, Inc.

<b>Disease Area</b>	Oncology
<b>Product Type</b>	Drug-conjugate
<b>Indication</b>	CD171 (L1CAM)-positive Solid tumor
<b>Target</b>	CD171 (L1CAM)
<b>Mechanism of Action</b>	Binding to CD171 (L1CAM) → Internalization → Cleaved and released active payload in lysosome → Cancer cell death by payload
<b>Competitiveness</b>	<ul style="list-style-type: none"><li>• Class: First-in-class.</li><li>• Anti-CD171 mAb (Ab612): Phase I IND approval in KOREA, Completion of GMP production process in 500 L scale.</li><li>• Ab612-MMAE (IC50): 100-fold lower than Kadcylla in HER2 (+) breast cancer cells, Excellent cytotoxicity in HER2 (low) and TNBC.</li><li>• Ab612-MMAE, Ab612-Dxd: Similar in vivo efficacy with Enhertu in JIMT-1-bearing CDX mouse model, Excellent stability.</li></ul>
<b>Development Stage</b>	<b>Lead</b>
<b>Route of Administration</b>	Intravenous infusion
<b>Key Data</b>	